ANKA BIO held the "AK1012 Inhalation Solution Phase II/III Clinical Trial Investigator Meeting" and the "Human Interferon α2b Spray Phase III Clinical Trial Investigator Meeting" in Xiamen, with both products focusing on respiratory viral infections in children entering the clinical validation sprint phase simultaneously. The two products that have initiated Phase III clinical trials target common and urgently needed disease areas in children. Among them, AK1012 Inhalation Solution is an improved new formulation of the company's already marketed product "Human Interferon α2b Injection," intended for the treatment of lower respiratory tract infections in children caused by respiratory syncytial virus. The Human Interferon α2b Spray is intended for the treatment of herpetic pharyngitis in children